ACCC COVID-19 Resource Center & Listserv
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Iowa's MULTIDISCIPLINARY CANCER CARE TEAM and the PATIENTS THEY SERVE since 1992
Meetings & Education
IOS Allied Health Professional Award
Financial Advocacy & Patient Assistance
IOS Advocacy Support
Patient Advocacy Organizations
IOS Quality Award Program
State & Federal Resources
Find A Clinical Trial
Off-Label Use Literature
National Professional Organizations
IOS Corporate Members
Become a Corporate Member
Industry News Archive
FDA Approves Padcev (enfortumab vedotin-ejfv) for Advanced Urothelial Cancer
On Dec. 18, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Padcev (enfortumab vedotin-ejfv), a Nectin-4-directed antibody and microtubule inhibitor conjugate, meaning the drug specifically targets cancer cells – in this case, the cell adhesion molecule Nectin-4, which is highly expressed in urothelial cancers.
Padcev is indicated for the treatment of locally advanced or metastatic urothelial cancer in adults who have previously received a PD-1 or PD-L1 inhibitor and a platinum-containing chemotherapy. Platinum-containing chemotherapy, PD-1 and PD-L1 inhibitors are standard treatments for patients with bladder cancer, the sixth most common cancer in the U.S. Urothelial cancer, which accounts for more than 90% of bladder cancers, begins in cells that line the bladder and nearby organs. Padcev is a new type of therapy for patients with advanced urothelial cancer whose disease has progressed on chemotherapy and immunotherapy.
Read FDA announcement
Tweets by OSSatACCC